CN108117593A - A kind of people ZNF295 polypeptides and its preparation method for antibody - Google Patents
A kind of people ZNF295 polypeptides and its preparation method for antibody Download PDFInfo
- Publication number
- CN108117593A CN108117593A CN201611112736.3A CN201611112736A CN108117593A CN 108117593 A CN108117593 A CN 108117593A CN 201611112736 A CN201611112736 A CN 201611112736A CN 108117593 A CN108117593 A CN 108117593A
- Authority
- CN
- China
- Prior art keywords
- znf295
- antibody
- terminal
- people
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses the preparation method of a kind of special people ZNF295 polypeptides of N-terminal and antibody, belong to the biological products of the experiment in vitro characterized by antibody.The amino acid sequence of the special people's ZNF295 polypeptides of N-terminal is:QSLFTNKENESQTV.Resist and be prepared as follows into ZNF295 polypeptide antibodies:(1) people ZNF295 Characterization of antigenic epitopes;(2) people ZNF295 N-terminals Peptide systhesis;(3) synthesis polypeptide is crosslinked with carrier protein;(4) rabbit-anti people's ZNF295 polypeptide antibodies are prepared;(5) collect, the isolated serum containing antibody, antibody purification is to get to anti-human ZNF295 polypeptide antibodies.The anti-human ZNF295 synthesis of polypeptide antibody potency of N-terminal prepared by the present invention specifically is high, affinity is strong, specificity is good, can occur to specifically bind reaction with natural human ZNF295;Manufacturing cost is low;Antibody after purification can be used for Western blotting and immunohistochemistry.The antibody is the basic research of ZNF295 albumen, for example the characteristic to ZNF295, function, express spectra and the analysis of content and its research of relevant disease provides an important instrument.
Description
1. technical field
The present invention relates to a kind of polypeptide and its preparation method for antibody, this antibody is mainly used for the inspection of native protein antigen
It surveys.
2. background technology
1) ZNF295 functions:Down syndromes (Down Syndrome), also known as 21- Trisomies (21 trisomy
Syndrome) or mongolism, it is a kind of most common clinical hereditary metabolic disorders, the incidence in life birth baby is
0.12-0.16%.Cytogenetic Features are in three signs for No. 21 chromosome, are occurred mainly since reproduction cell is subtracting
With the period of the day from 11 p.m. to 1 a.m or fertilized eggs, No. 21 chromosomes generations in mitosis do not separate for speed division formation, and embryoid body is made to exist into the cell
One No. 21 additional chromosome.Primary Study finds that the overexpression of ZNF295 albumen is considered No. 21 additional with this
Chromosome is related, therefore, the further investigation to ZNF295 albumen, the pathogenesis sick to this, clinical classification, precisely treatment and pre-
It is anti-to have important impetus.(Gene.2013 Jan;10:125(2)-25).
2) ZNF295 antibody products information:Through retrieving, there is the polyclonal antibody of ZNF294 albumen in the market, but these are anti-
The epitope of body is different with the epitope of my company.
3) application of ZNF295 antibody:Primary Study finds that overexpression of the ZNF295 albumen in Down syndromes is
The exercising result of this additional No. 21 chromosome.This suggests that us, which is possible in the sick generation, evolution
In, it plays an important role, is likely to become a potential disease with basic research and clinical value soon in the future
Therefore sick marker, researches and develops polypeptide corresponding with its target protein and its specific antibody, will be to studying the albumen and its in the disease
Occur, effect and clinical precisely treatment and prevention in evolution provide accurate reliable instrument and material, have important
Meaning.
3. the content of the invention
The present invention provides a kind of ZNF295 polypeptides, sequence is:QSLFTNKENESQTV.It is prepared with this polypeptide anti-
ZNF295 antibody can be in Western blotting (Western blot) analysis in specific recognition tissue or cell natural ZNF295
Albumen.
Anti- ZNF295 antibody through the following steps that obtain:
Step 1:The analysis and design of peptide sequence:Using DNAstar softwares to the amino acid sequence of ZNF295 albumen into
Row Characterization of antigenic epitopes mainly assesses hydrophily, antigenicity, surface possibility, and the indexes such as flex region were prepared anti-in conjunction with the past
The practical experience of body, finally as synthesis polypeptide amino acid sequence, sequence is definite ZNF295 albumen 56-69 positions 14 amino acid
QSLFTNKENESQTV。
Step 2:Peptide systhesis and crosslinking:Desired polypeptides are synthesized using ACT396 fully-automatic multi-channels Peptide synthesizer, and
It is identified using mass spectrum;To enhance the antigenicity of polypeptide, ZNF295 polypeptides and carrier protein KLH are handed over using Sulfo-SMCC
Connection method is crosslinked.
Step 3:It is prepared by polypeptide immune and antiserum:By the ZNF295-KLH after crosslinking and Freund's adjuvant mixing and emulsifying,
New zealand rabbit back carries out intradermal injection immunity, and booster immunization repeatedly, stops until blood examination is taken to survey when antibody titer reaches standard
It is immune.
Step 4:Antibody purification:After experimental rabbit antibody titer reaches standard, using heart extracting blood, antiserum is separated, is used
After Protein A purifying whole antibodies, further using peptide affinity purification, target antibody is obtained.
Anti- ZNF294 antibody through the following steps that identification:
Step 1:Western blotting:Using the ZNF294 antibody obtained as primary antibody, using the western blotting method of standard,
Confirm the antibody can with the natural ZNF294 protein-interactings after denaturation, available for western blot test.
4. description of the drawings
Fig. 1 is western blot figure (Western blot)
5. specific embodiment
1. the analysis and design of peptide sequence
Characterization of antigenic epitopes is carried out to the amino acid sequence of ZNF294 albumen using DNAstar softwares, is mainly assessed hydrophilic
Property, antigenicity, surface possibility, the indexes such as flex region prepared the practical experience of antibody in conjunction with the past, consider amino acid structure
Complexity, oxidizable degree synthesize difficulty, and amino acid classification and distribution etc. finally determine ZNF294 albumen 49-62 positions 14
Amino acid is as synthesis polypeptide amino acid sequence, sequence GKNKQRTKGNLRPS.Meanwhile to ensure that later stage polypeptide is crosslinked carrier
Albumen and peptide affinity purification increase a cysteine C in N-terminal, and final peptide sequence to be synthesized is C-
GKNKQRTKGNLRPS。
2. Peptide systhesis and crosslinking
Using ACT396 fully-automatic multi-channel Peptide synthesizers, desired polypeptides are automatically synthesized according to the program woven, it will
Polypeptide after synthesis is dissolved in 50% acetonitrile, is identified using mass spectrograph, and it is purpose polypeptide to confirm obtained polypeptide.Using
Carrier protein KLH is crosslinked by Sulfo-SMCC as crosslinking agent with synthesis polypeptide:10mg KLH is taken to be dissolved in 0.5ml ultra-pure waters
In;3mg sulfo-SMCC is taken to be dissolved in 0.5ml ultra-pure waters, with 3MNaOH tune pH value 7 or so.In mixing,
Sulfo-SMCC solution is slowly added to dropwise in KLH solution, rotates mixing reactant 30min at room temperature.It will be completely reacted
Sulfo-SMCC/KLH mixed liquors are loaded in advance with level pad (0.05M PB, pH6.0) equilibrated 30min's
In Sephadex G25 columns, light grey eluent, that is, the sulfo-SMCC/KLH solution activated are collected.With 200ul PBS
(pH7.3) 2mg cross linking polypeptides are treated in dissolving, and the sulfo-SMCC/KLH complex solutions of 0.2 volume are added in polypeptide solution,
PH value is adjusted to 7.3, when rocked at room temperature 4 is small, after -70 DEG C of freezings, with freeze dryer freeze 24 it is small when standby use.It is examined by Ellman methods
Polypeptide sulfydryl determines polypeptide cross-linking efficiency before and after test cross connection.
3. prepared by polypeptide immune and antiserum
The 400 μ g of KLH- polypeptides being crosslinked are dissolved in 400 μ l phosphate buffers (0.01M PBS), are added in equal volume not
Family name's Freund's complete adjuvant is fully emulsified (to indiffusion in water).Using 3 months rabbit ages, the health of weight 1.75-2.25Kg was new
Western blue rabbit is immunized, and is carried out back intradermal injection immunity, at least to be injected 20 points or more.After first immunisation 3 weeks, by 300 μ g
Polypeptide is dissolved in 300 μ l phosphate buffers (0.01M PBS), intracutaneous with the fully emulsified rear progress of the incomplete Freund's adjuvant of equivalent
It is immune, as first time booster immunization, it is desirable that back intradermal injection immunity will at least inject 15 points or more.Second 3 weeks immune
Afterwards, second of booster immunization is carried out, method and requirement are the same as first time booster immunization.After 1 week, blood is taken using auricular vein is micro,
With uncrosslinked synthesis polypeptide coated elisa plate, indirect elisa method detection immune serum potency.It repeats booster immunization and potency is surveyed
Fixed, until serum titer reaches more than 1: 60000, using heart extracting blood, standard method obtains antiserum.
4. antibody affinity purification
(1), TIgG is purified:50% Protein-A Sepharose suspensions 10ml is added to 30ml layers with pipettor
It analyses in column, removes top lid and bottom cap, the bed volume after liquid outflow is 5ml, then with 25ml deionized water rinsings 3 times.
Corresponding serum 10ml is taken out, is added in after being mixed with 2ml PBS in 30ml chromatographic columns, room temperature (20-25 DEG C) on impeller
When mixed 1 is small, blood serum sample is allowed to flow out.Purify washing lotion with 15ml again and wash chromatographic column 3 times, add in 10ml eluents and eluted.
(2), peptide affinity purification:1ml Sulfo-link gel suspensions (0.5ml gels) are added in chromatographic column, are treated in column
Dried liquid stream rinses chromatographic column with 4ml coupling buffers.The ZNF295 polypeptides synthesized with the dissolving of 1ml coupling buffers, and add in
Chromatographic column adds 1ml coupling buffers into chromatographic column, room temperature overturn mixing 1 it is small when.Layer is rinsed with 6ml coupling buffers
Column is analysed, 3ml confining liquids are then added in, when room temperature mixing 1 is small.It rinses chromatographic column 3 times, 6ml IgG is then added in into chromatographic column
And 3ml PBS, room temperature overturn mixing 1 it is small when.Chromatographic column is rinsed with PBS 3 times, then with 2ml elutions.By what is obtained
Antibody purification is packed into 4 DEG C of dialysis in bag filter.Dialysed overnight, then 4000rpm × 35min centrifugations collect supernatant except precipitation.With
Indirect elisa method measures antibody titer and measures protein concentration with Bradford methods.
Anti- ZNF295 antibody through the following steps that identification:
1. immunoblotting assay
PAGE gel is prepared according to standard method, by the cell or Tissue Lysis that 5 μ l protein concentrations are 5mg/ml
Liquid is loaded successively, constant pressure 80V about 30 minutes, when sample ran concentration matrix sheet in straight line, changes 160V voltages, electrophoresis
Electrophoresis is terminated when running out of separation gel (about 60 minutes) completely to bromophenol blue indicator, turns 80 using electric transferring film method constant pressure 100V electricity
Minute transferring film is to pvdf membrane.Using the ZNF294 antibody obtained as primary antibody, concentration is used to be obtained for 1 μ l/ml with above-mentioned transferring film
Antigen chip hybridize at room temperature 1 it is small when, then with HRP mark goat anti-rabbit antibody hybridize at room temperature 1 it is small when, use
ECL development processes develop the color, and are developed the color and are exposed with X pieces in darkroom, obtain immunoblot results.
Polypeptid acid sequence table
Gln Ser Leu Phe Thr Asn Lys Glu Asn Glu Ser Gln Thr Val。
Claims (6)
1. a kind of people ZNF295 polypeptides, it is characterised in that the amino acid sequence of polypeptide is:QSLFTNKENESQTV.
2. a kind of preparation method for antibody of anti-human ZNF295 polypeptides, it is characterised in that sequent synthesis N-terminal is repaiied as described in claim 1
Peptide is adornd, the N-terminal modified peptides of synthesis and carrier protein are crosslinked, animal is immunized with crosslinked peptide, the blood of immune animal is taken to prepare and is resisted
Serum isolates and purifies IgG from serum, wherein the N-terminal is modified to N-terminal one cysteine of increase in amino acid sequence
Residue.
3. preparation method for antibody according to claim 2, it is characterised in that carrier protein for keyhole limpet hemocyanin (KLH) or
Bovine serum albumin(BSA) (BSA).
4. preparation method for antibody according to claim 2, it is characterised in that N-terminal modified peptides by crosslinking agent by its sulfydryl with
Carrier protein amino covalence is crosslinked.
5. preparation method for antibody according to claim 2, it is characterised in that after crosslinking peptide and immunologic adjuvant mixing and emulsifying,
Rabbit back is subcutaneously injected by multiple spot, and through secondary Yi Shang booster immunization, the potency of serum is more than 1: 10000.
6. preparation method for antibody according to claim 2, it is characterised in that by ammonium sulfate precipitation, albumin A affinity purification
And peptide affinity purification can obtain the IgG of high-purity from antiserum.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611112736.3A CN108117593A (en) | 2016-11-30 | 2016-11-30 | A kind of people ZNF295 polypeptides and its preparation method for antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611112736.3A CN108117593A (en) | 2016-11-30 | 2016-11-30 | A kind of people ZNF295 polypeptides and its preparation method for antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108117593A true CN108117593A (en) | 2018-06-05 |
Family
ID=62226490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611112736.3A Withdrawn CN108117593A (en) | 2016-11-30 | 2016-11-30 | A kind of people ZNF295 polypeptides and its preparation method for antibody |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108117593A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105985422A (en) * | 2015-01-30 | 2016-10-05 | 天津奥维亚生物技术有限公司 | Human SH3BGR polypeptide and preparation method for antibody thereof |
-
2016
- 2016-11-30 CN CN201611112736.3A patent/CN108117593A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105985422A (en) * | 2015-01-30 | 2016-10-05 | 天津奥维亚生物技术有限公司 | Human SH3BGR polypeptide and preparation method for antibody thereof |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "NP_065778.3", 《GENBANK》 * |
CLAIRE SPELLMAN ET AL: "Expression of trisomic proteins in Down syndrome model systems", 《GENE》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104862283B (en) | The monoclonal antibody of a pair of of high specific high-affinity combination human muscle hemoglobin and its application | |
CN107022029A (en) | The monoclonal antibody of highly-specific highly Sensitive Detection alpha-fetoprotein and kit and application | |
CN110272502B (en) | Immunogen, hybridoma cell secreting anti-cardiac troponin I monoclonal antibody, preparation method, monoclonal antibody and application | |
CN103360468B (en) | Preparation method for SCD1 polypeptide and anti-goose SCD1 polypeptide polyclonal antibody | |
CN105985422A (en) | Human SH3BGR polypeptide and preparation method for antibody thereof | |
CN101880316B (en) | Human RBPMS polypeptide and preparation method of antibody thereof | |
CN110317270A (en) | Antitoxin snake PLA2Protein antibodies and its application | |
CN108148127A (en) | A kind of people MAP3K7IP2 polypeptides and its preparation method for antibody | |
Brandtzaeg | HUMAN SECRETORY IMMUNOGLOBULINS: 4. Quantitation of Free Secretory Piece | |
CN110183530A (en) | Leptin immunogene, hybridoma, monoclonal antibody, polyclonal antibody and application | |
CN108148124A (en) | A kind of Human HNRPA 0 polypeptide and its preparation method for antibody | |
Johansson et al. | Development of monoclonal antibodies for detection of antisecretory factor activity in human plasma | |
JP2000515854A (en) | Method for measuring the presence of brain protein S-100 | |
CN101928332A (en) | Preparation method of Human HNRPA0 polypeptide and antibody thereof | |
CN108148126A (en) | A kind of people C21ORF13 polypeptides and its preparation method for antibody | |
CN113832132B (en) | Solder tip SVMP protein specific short peptide, solder tip SVMP protein antibody and snake bite detection kit | |
CN101928334B (en) | Preparation method of mouse Ehf polypeptide and antibody thereof | |
CN108117593A (en) | A kind of people ZNF295 polypeptides and its preparation method for antibody | |
CN108117592A (en) | A kind of people ZNF294 polypeptides and its preparation method for antibody | |
CN108148125A (en) | A kind of human EIF 4 H polypeptide and its preparation method for antibody | |
CN101392017A (en) | Isolation and purification method of main allergic protein of humulus pollen | |
CN101392023A (en) | Main allergic protein of humulus pollen | |
CN101928333A (en) | Human EIF4H polypeptide and preparation method of antibody thereof | |
US20100221742A1 (en) | Novel cancer associated antibodies and their use in cancer diagnosis | |
CN106167793A (en) | A kind of people's GTPBP9 polypeptide and preparation method for antibody thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180605 |